The Future of Early-Stage Deep Tech Investments in Europe
Join the conversation with Alexander Schwartz and Ingrid Kelly Spillmann
2006 was a fantastic year. The colossal crisis that hit the western world as the dot.com bubble burst was long forgotten, and capital seemed to be available at every corner. Nobody was aware yet of the coming doomsday of the global financial sector in 2008.
Many new companies started to take off in the first decade of the new millennium in life science.
Intercell- founded in 1998 - did its IPO on the Austrian stock market in 2005. Werner Lanthaler led the IPO as a CFO and built Evotec into a global innovation engine.
These are just a few examples of companies that started alongside major financial crises, like the burst of the dot.com bubble and the 2008 financial crisis after the collapse of the Lehman brothers.
Starting a company was a massive adventure in those years as no start-up ecosystem existed like Europe has today. Also, finding mentors, coaches, and seasoned life science investors was hard work when the ecosystem was young.
A lot has changed since 2006; the ecosystem evolved into a great support system for scientific founders, with the first successes of life science companies; more knowledge about the secrets of structuring deep tech companies is available than two decades ago.
But is the world perfect now, or are there still challenges that need to be overcome to create a better breeding ground for deep tech teams and their technologies that have the potential to change the world?
McKinsey digs deeper into Biotech.
A lot of work still needs to be done, and I wanted to look at these hot topics with people who are proficient in the field.
IST Austria and IST Cube
In 2009 - also in the first decade - development companies started, and one of the world’s best research institutions was officially inaugurated. The first research groups moved into the novel campus in Lower Austria.
Meanwhile, IST has grown into one of the world’s best research organizations and recently secured funding until 2036.
In 2013 IST hired Markus Wanko to organize the Tech Transfer for the Institution, and he started the Early Stage Deep Tech Investment Fund IST Cube in 2017.
IST Cube is one of the first deep tech early-stage investment Funds in Austria, with the mission to invest in an area usually not touched by Venture Capital Firms.
Let’s Chat About Early Stage Investments
Since its inception, IST Cube has been recognized in Pitchbook with 18 investments and one exit.
Recently, in February 2021, IST Cube closed another financing round of 40 Million euros - Fresh Capital for investments in novel teams with novel technology.
I am thrilled that
join the Podcast for a pleasant conversation about
The Future of Early Stage Deep Tech Investments in Europe
Do you want to learn more about the European Life Science Industry, IST Cube, and the situation of Early Stage Investments in Europe?
Then join our conversation:
Visualizing Global Demand for Lithium Lithium is one of the most in-demand commodities in the world today. With the ongoing shift to electric vehicles (EVs) and clean energy technologies, governments and EV manufacturers are rushing to secure their supply chains as demand for lithium soars. Read more…
The University Spinout Report 2021: which UK universities top the rankings for turning innovation into commercial success? UK universities rank among the top universities globally, comprising four of the top 10, according to leading authority QS World University Rankings. UK institutions are renowned for world-changing innovation, particularly in fields such as pharmaceuticals, engineering and IT. Read more…
Merck pill seen as 'huge advance,' raises hope of preventing COVID-19 deaths An experimental antiviral pill developed by Merck & Co (MRK.N) could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated. Read more…
More information and link to registration in
In the last episodes, I have talked with investors and decision-makers of the pharmaceutical industry about the importance of having a vision and passion for the life science company.
I want to explore this topic further and ask the life science entrepreneur Christof Goetz to chat with me about finding your vision and passion for your company.
Christof is a Serial Entrepreneur with more than 20 years of experience managing complex business, software, and hardware development projects.
MyMind is a life science company based in Vienna. MyMinds vision is to help people with neurological impairments to live towards their full brain potential with affordable and easy-to-use brain training and assessment technology. MyMind currently focuses on Autism Spectrum Disorders (ASD), whether comorbid with Attention Deficit Hyperactivity Disorder (ADHD), Intellectual Disability (low IQ), Epilepsy, and Anxiety. Subsequently, MyMind will extend to other neurological issues such as dementia or stroke recovery.
Christof Goetz (https://www.linkedin.com/in/christofgoetz/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
CS Life Science Invest (https://lnkd.in/eyhWK7H)
My Mind GmbH (https://www.linkedin.com/company/mymindvienna/)
These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!
You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren’t finding this valuable.
Nothing in this email is intended to serve as financial advice. Do your own research.